BTIG analyst Ryan Zimmerman maintained a Buy rating on Vicarious Surgical (RBOT – Research Report) today and set a price target of $5.00. The company’s shares closed last Friday at $0.43.
According to TipRanks, Zimmerman is a 4-star analyst with an average return of 4.5% and a 39.96% success rate. Zimmerman covers the Healthcare sector, focusing on stocks such as Vericel, Stryker, and Glaukos.
Vicarious Surgical has an analyst consensus of Moderate Buy, with a price target consensus of $4.50.
See the top stocks recommended by analysts >>
The company has a one-year high of $3.99 and a one-year low of $0.41. Currently, Vicarious Surgical has an average volume of 1.08M.
Based on the recent corporate insider activity of 99 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of RBOT in relation to earlier this year.
TipRanks has tracked 36,000 company insiders and found that a few of them are better than others when it comes to timing their transactions. See which 3 stocks are most likely to make moves following their insider activities.
Vicarious Surgical (RBOT) Company Description:
D8 Holdings Corp is a blank check company.
Read More on RBOT:
